SBIR/STTR Research Award
Continue, Expand, and Refine Research and Development of a Hydromorphone Autoinjector
Award amount
$1,799,613Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2023Award details
- Awarding agency
- Department of Defense
- Branch
- Air Force
- Recipient company
- RX BANDZ, INC.
- Proposal award date
- 2023-09-16
- Contract end date
- 2025-09-18
- UEI
- DXRED7S6FVE9
- Solicitation number
- X21.1
- Topic code
- AF211-DCSO1
Research abstract
The proposed TACFI effort seeks to continue, expand and refine the Phase II achievements with the goal of producing a hydromorphone auto-injector requested by the Air Force for immediately available point-of-injury care on remote and austere battlefields.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Shelf-life Extension for Emergency Medication
- Stop The Bleed - Save the Warfighter! : Intramuscular Auto-Injector Delivery of Tranexamic Acid (TXA) on the Battlefield
- Extended Utilization of Lifesaving Medications via Autoinjector
- Auto Injector Administration of Ketamine for Critically Injured Airmen
- Life-Saving Mini Auto-Injector to Deliver Epinephrine
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- TACFI KestrelX
- Low-Cost Rapid-Cadence Hypersonic Launch
- Electrified Propulsion Aircraft Rapid Design Tools
- Low Probability of Intercept/Low Probability of Detection (LPI/LPD) Multi-band Mesh Networks
- Space Prognostic AI Custodian Ecosystem (SPAICE) - TACFI
Research funding history
12 SBIR/STTR records share this UEI (2020–2023). Reported award amounts total $6,990,569. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Defense